Description
Introduction
Fuelled by the pandemic flu threat, the influenza market has expanded rapidly in recent years. This growing commercial opportunity has encouraged companies to develop new te...(more)
Description
THIS REPORT:
Provides a thorough evaluation of the market for influenza vaccines, therapeutics, and diagnostics
Offers a global analysis, with emphasis on U.S. data, and a fiv...(more)
Description
Introduction
Drug therapies for immune disorders span an enormous price range—from a few cents per day to tens of thousands
of dollars per year. Not surprisingly, payers impose restricti...(more)
Description
The Merger and Acquisition Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the merger and acquisition (M&A) agreements entered int...(more)
Description
The report provides a detailed understand and analysis of how and why companies enter co-promotion and co-marketing deals. The majority of deals are multicomponent whereby the licensor retains either ...(more)
Description
The Manufacturing and Supply Agreements in Pharma, Biotech and Diagnostics, 2nd edition report provides comprehensive understanding and unprecedented access to the manufacturing and supply agreements ...(more)
Description
Key Trends in Drug-Diagnostic Co-Development
Identifying collaborative opportunities and navigating regulatory challenges
Report Overview
The development of genomics-based ...(more)
Description
The Oncology Partnering Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the oncology partnering agreements entered into by the wor...(more)
Description
REPORT HIGHTLIGHTS
Description
Introduction
Targeted cancer therapies have achieved phenomenal growth, and many MAb-based immunotherapies are blockbusters
or mega-blockbusters. This market success is due not only to ...(more)
Description
In BMI’s updated Business Environment Rankings (BER) for Q109, Peru has slipped from second-last tolast position in the Americas matrix, thus remaining one of the least attractive pharmaceutical...(more)
Description
The driving force behind revenue in biotechnology and pharmaceutical companies is the product. Since the drugs being sold on the market are the most significant assets these companies own and operate...(more)
Description
STUDY OVERVIEW
Commercial success of pharmaceutical products today depends increasingly upon understanding the needs of the commercial and government payers in the highly
Description
Introduction
Long being regarded as an unattractive market, vaccines have re-emerged as successful growth driver for Big Pharma. The launch and rapid uptake of novel, high-price product...(more)
Description
Introduction
This databook provides insight into the top 10 companies in France life sciences industry in terms of their estimated IT spend.
Scope
Description
The biotechnology and pharmaceutical sectors as we know them will soon cease to exist. Companies in these
sectors have come face-to-face with the harrowing ordeals of a global recession. Four stresses...(more)
Description
Euromonitor International's Eye Care in China report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data (2003-2008), allowin...(more)
Description
Euromonitor International's Wound Treatments in Ireland report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data (2003-200...(more)
Description
This report analyzes the global market for Cancer Therapies in US$ Billion. The specific product segments analyzed are Chemotherapy, Targeted Therapy, Hormonal Therapy, and Immunotherapy. Annual forec...(more)
Description
Introduction
Can radical changes to the structures and strategies of pharmaceutical R&D operations—such as
creating more entrepreneurial environments modeled upon biotech companies&mdash...(more)
Description
Romania ranks joint fifth in BMI’s Business Environment Rankings for Central and Eastern Europe,highlighting the market’s attractiveness for drugmakers. While per capita spending remains r...(more)
Description This report comprises defined and up to date development strategies for 409 protein kinase drugs (990 projects) within the portfolio of 160 investigators, from Ceased to Marketed. The report extens...(more)
Description
From BHD44mn (US$114mn) in 2008, BMI forecasts that Bahrain’s pharmaceutical market will expandto be worth BHD61mn (US$160mn) in 2018. While the market will remain small in absolute terms, rapid...(more)
Description Ion channels represent a significant opportunity to address an underexploited class of therapeutic targets. Nearly 150 novel ion channel modulators are reported to be in clinical development. This ...(more)
Description
There are some green shoots of hope appearing in the wreckage of Zimbabwe’s healthcare sector, as anumber of foreign companies are considering re-investing in the country. Foreign drugmakers hav...(more)
Description
In BMI’s Business Environment Ratings table for the 17 countries in the MEA region, Egypt occupies animproved 9th position, up two places in relation to the previous quarter and now, significant...(more)
© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd 
All rights reserved. Terms and Conditions | Contact us
